Professor Dyfrig Hughes
Athro mewn Ffarmacoeconomeg / Cyfarwyddwr Ymchwil
- Published
Assessing the association between compliance and therapeutic failure for antiretroviral drugs in HIV positive patients
Hughes, D. & Hughes, D. A., 1 May 2007.Research output: Contribution to conference › Paper
- Published
Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?
Hughes, D. & Hughes, D. A., 1 Jun 2003.Research output: Contribution to conference › Paper
- Published
Cost minimization of on-demand maintenance therapy with proton pump inhibitors in nonerosive gastroesophageal reflux disease.
Hughes, D., Hughes, D. A., Marchetti, M. & Colombo, G., 1 Feb 2005, In: Expert Review of Pharmacoeconomics and Outcomes Research. 5, 1, p. 29-38Research output: Contribution to journal › Article › peer-review
- Published
Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations.
Hughes, D., Hughes, D. A., Cowell, W., Koncz, T. & Cramer, J., 1 Nov 2007, In: Value in Health. 10, 6, p. 498-509Research output: Contribution to journal › Article › peer-review
- Published
Statistical comments are unfounded.
Hughes, D., Hughes, D. A., Cowell, W., Koncz, T. & Cramer, J., 1 Mar 2008, In: Value in Health. 11, 2, p. 346Research output: Contribution to journal › Article › peer-review
- Published
Abolition of prescription copayments in Wales: an observational study on dispensing rates.
Hughes, D., Cohen, D., Alam, M. F., Dunstan, F. D., Myles, S., Hughes, D. A. & Routledge, P. A., 1 Aug 2010, In: Value in Health. 13, 5, p. 675-680Research output: Contribution to journal › Article › peer-review
- Published
Biosimilars: Evidential standards for health technology assessment.
Hughes, D. & Hughes, D. A., 1 Jan 2009.Research output: Contribution to conference › Paper
- Published
Public meetings of the NICE appraisals committee
Hughes, D. & Hughes, D. A., 1 Dec 2007.Research output: Contribution to conference › Paper
- Published
Modelling changes in first line antimalarial therapy
Hughes, D. & Hughes, D. A., 1 Sept 2003.Research output: Contribution to conference › Paper
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Pegfilgrastim (Neulasta) for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
Use of PK-PD modelling to predict the impact of non-compliance
Hughes, D. & Hughes, D. A., 1 Nov 2003.Research output: Contribution to conference › Paper
- Published
Estimating Drug Costs in Economic Evaluations in Ireland and the UK: An Analysis of Practice and Research Recommendations.
Hughes, D., Hughes, D. A., Tilson, L. & Drummond, M. F., 1 May 2009, In: Pharmacoeconomics. 27, 8, p. 635-643Research output: Contribution to journal › Article › peer-review
- Published
Management of Patients Symptomatically Unresponsive to Levothyroxine: Natural Desiccated Thyroid Extract or the Combination of Levothyroxine and Liothyronine? A Research Priority
Hughes, D., Livingston, M. & Heald, A., Sept 2020, In: Experimental and Clinical Endocrinology & Diabetes . 128, 9, p. 596-598Research output: Contribution to journal › Letter › peer-review
- Published
Economics of pharmacogenetic guided treatments: Underwhelming or overstated?
Hughes, D., May 2018, In: Clinical Pharmacology and Therapeutics. 103, 5, p. 749-751Research output: Contribution to journal › Article › peer-review
- Published
Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence.
Hughes, D., Hughes, D. A. & Dubois, D., 1 Jan 2004, In: Pharmacoeconomics. 22, 16, p. 1047-1059Research output: Contribution to journal › Article › peer-review
- Published
Less is more: Medicines that require less frequent administration improve adherence, but are they better?
Hughes, D. & Hughes, D. A., 1 Jan 2006, In: Pharmacoeconomics. 24, 3, p. 211-213Research output: Contribution to journal › Article › peer-review
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Deferasirox (Exjade) for the treatment of chronic iron overload due to blood transfusions.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
Clinical Pharmacology: Special safety considerations in drug development and pharmacovigilance.
Hughes, D., Atuah, K. N., Hughes, D. A. & Pirmohamed, M., 1 Jan 2004, In: Drug Safety. 27, 8, p. 535-554Research output: Contribution to journal › Article › peer-review
- Published
Valuations of epilepsy-specific health states: a comparison of patients with epilepsy and the general population
Hughes, D., Mulhern, B., Rowen, D., Snape, D., Jacoby, A., Marson, T., Hughes, D. A., Baker, G. & Brazier, J., 1 Jul 2014, In: Epilepsy and Behavior. 36, p. 12-17Research output: Contribution to journal › Article › peer-review
- Published
All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Chronic, accelerated or blast phase CML.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2007, 2007 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
A systematic review and empirical analysis of the relation between dose and duration of drug action.
Hughes, D., Hughes, D. A. & Aronson, J. K., 1 Jan 2009, p. TP40.Research output: Contribution to conference › Paper
- Published
The economics of evergreening.
Hughes, D. & Hughes, D. A., 1 Jan 2009.Research output: Contribution to conference › Paper
- Published
Drugs for exceptionally rare diseases: do they deserve special status for funding?
Hughes, D., Tunnage, B. & Yeo, S. T., 1 Nov 2005, In: QJM - An International Journal of Medicine. 98, 11, p. 829-836Research output: Contribution to journal › Article › peer-review
- Published
Impact of the abolition of the prescription charge in Wales.
Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Jan 2009.Research output: Contribution to conference › Paper
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Emtricitabine/tenofovir DF (Truvada)
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2007, 2007 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group
Hughes, D., Linck, P. G., Hiligsmann, M., Salas, M., Hughes, D. A., Manias, E., Gwadry-Sridhar, F. H., Linck, P. & Cowell, W., 1 Dec 2013, In: Osteoporosis International. 24, 12, p. 2907-2918Research output: Contribution to journal › Article › peer-review
- Published
Public funding of drugs for orphan diseases
Hughes, D. & Hughes, D. A., 1 Jul 2005.Research output: Contribution to conference › Paper
- Published
Pharmacokinetic-Pharmacodynamic modelling of Lapdap (CPG-DDS) combination.
Hughes, D., Hughes, D. A., Watkins, B. & Winstanley, P., 1 Jan 2001, 2001 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
Pharmacoeconomic evaluations in Ireland, Scotland and Wales: A Celtic perspective on pharmaceutical assessment
Hughes, D., Hughes, D. A., Drummond, M., Tolley, K. & Ryan, M., 1 Oct 2007.Research output: Contribution to conference › Paper
- Published
Rationing of drugs for rare diseases.
Hughes, D. & Hughes, D. A., 1 Jan 2006, In: Pharmacoeconomics. 24, 4, p. 315-316Research output: Contribution to journal › Article › peer-review
- Published
Biosimilars: Evidential standards for health technology assessment.
Hughes, D. & Hughes, D. A., 1 Mar 2010, In: Clinical Pharmacology and Therapeutics. 87, 3, p. 257-261Research output: Contribution to journal › Article › peer-review
- Published
Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments - piloting a discrete choice experiment
Hughes, D., Myles, S., Hughes, D. A., Longo, M. & Lisles, C., 1 Jun 2006.Research output: Contribution to conference › Paper
- Published
Climate influences on the cost-effectiveness of vector-based interventions against malaria in elimination scenarios
Hughes, D., Parham, P. E. & Hughes, D. A., 16 Feb 2015, In: Philosophical Transactions B: Biological Sciences. 370, 1665Research output: Contribution to journal › Article › peer-review
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
The Population Pharmacokinetics of R and S-Warfarin: Effect of Genetic and Clinical Factors
Hughes, D., Lane, S., Al-Zubiedi, S., Hatch, E., Matthews, I., Jorgensen, A. L., Deloukas, P., Daly, A. K., Aarons, L., Ogungbenro, K., Kamali, F., Hughes, D. A. & Pirmohamed, M., 1 Jan 2012, In: British Journal of Clinical Pharmacology. 73, 1, p. 66-76Research output: Contribution to journal › Article › peer-review
- Published
Orphan drugs revisited: author's response.
Hughes, D. & Hughes, D. A., 1 May 2006, In: Quarterly Journal of Medicine. 99, 5, p. 350-351Research output: Contribution to journal › Article › peer-review
- Published
Development of an economic model to evaluate the cost-effectiveness of rival therapies for treating Crohn’s disease.
Hughes, D., Kikuchi, T., Bodger, K. & Hughes, D. A., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Tenofovir disoproxil fumarate (Viread) for the treatment of hepatitis B.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
Adverse drug reactions in economic evaluations
Hughes, D. & Hughes, D. A., 1 Jan 2007, In: Value in Health. 10, 3, p. A109Research output: Contribution to journal › Article › peer-review
- Published
Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group
Hughes, D., Faulkner, E., Annemans, L., Garrison, L., Helfand, M., Holtorf, A. P., Hornberger, J., Hughes, D. A., Li, T., Malone, D., Payne, K., Siebert, U., Towse, A., Veenstra, D. & Watkins, J., 1 Dec 2012, In: Value in Health. 15, 8, p. 1162-1171Research output: Contribution to journal › Article › peer-review
- Published
Cost-utility analysis of on-demand rabeprazole and esomeprazole for non-erosive reflux disease
Hughes, D. & Hughes, D. A., 1 Nov 2003.Research output: Contribution to conference › Paper
- Published
Welsh Health Economics Network (WHEN): Scoping Report.
Hughes, D., Farr, A., O Ceilleachair, A., Cohen, D., Hughes, D. A. & Phillips, C., 1 Jan 2005, 2005 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
Understanding medication compliance and persistence from an economics perspective
Hughes, D., Elliot, R. A., Shinogle, J. A., Peele, P., Bhosle, M. & Hughes, D. A., 1 Jan 2008, In: Value in Health. 11, 4, p. 600-610Research output: Contribution to journal › Article › peer-review
- Published
Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?
Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Nov 2003, In: Value in Health. 6, 6, p. 749Research output: Contribution to journal › Article › peer-review
- Published
Decision-Makers’ Preferences for Approving New Medicines in Wales: A Discrete-Choice Experiment with Assessment of External Validity
Hughes, D., Linley, W. G. & Hughes, D. A., 1 Apr 2013, In: Pharmacoeconomics. 31, 4, p. 345-355Research output: Contribution to journal › Article › peer-review
- Published
Biosimilars: Evidential standards for health technology assessment.
Hughes, D. & Hughes, D. A., 1 Jan 2009.Research output: Contribution to conference › Paper
- Published
All Wales Medicines Strategy Group Final Appraisal Report – Emtricitabine (Emtriva)
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2007, 2007 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
Pharmacogenetic tests: the need for a level playing field
Hughes, D., Pirmohamed, M. & Hughes, D. A., 1 Jan 2013, In: Nature Reviews Drug Discovery. 12, 3-4Research output: Contribution to journal › Article › peer-review
- Published
Impact of Interventions on Medication Adherence and Blood Pressure Control in Patients with Essential Hypertension: A Systematic Review by the ISPOR Medication Adherence and Persistence Special Interest Group
Hughes, D., Gwadry-Sridhar, F. H., Manias, E., Lal, L., Salas, M., Hughes, D. A., Ratzki-Leewing, A. & Grubisic, M., 1 Jul 2013, In: Value in Health. 16, 5, p. 863-871Research output: Contribution to journal › Article › peer-review